-
LCLF1.0 Data
Study
phs003187
-
Phase 1 CX-5461 Trial (Canadian Cancer Trials Group Trial IND.231)
Study
EGAS00001006173
-
Multimodal Genomic Features Predict Outcome of Immune Checkpoint Blockade in Non-small Cell Lung Cancer
Study
EGAS00001003892
-
Comprehensive genomic and transcriptomic analysis of three synchronous primary tumours and a recurrence from a head and neck cancer patient
Study
EGAS00001004857
-
Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade
Study
EGAS00001004353
-
The evolution of hematopoietic cells under cancer therapy
Study
EGAS00001005234
-
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
Study
EGAS00001005984
-
UK renal cancer samples genotyped on Illumina OmniExpress BeadChip
Study
EGAS00001002336
-
Accumulation of copy number alterations and clinical progression across advanced prostate cancer
Study
EGAS00001006251
-
Therapy-Induced APOBEC3A Drives Evolution of Resistance to Targeted Therapies in Non-Small Cell Lung Cancer
Study
phs003256